Global Psoriasis Drug Market Size By Type (External Use, Oral), By Application (Hospital, Drugs Store), By Region, And Segment Forecasts, 2023 to 2032

The Global Psoriasis Drug Market was valued at USD 24.6 billion in 2023 and is projected to reach USD 47.8 billion by 2031, expanding at a CAGR of 8.7% during the forecast period from 2023 to 2031. Psoriasis, a chronic autoimmune condition affecting the skin, is increasingly prevalent globally, driven by genetic predisposition, lifestyle changes, and environmental triggers. The market is gaining momentum due to advancements in biologics, a growing number of pipeline drugs, and increasing awareness of early diagnosis and treatment.

Drivers:

1. Rising Prevalence of Psoriasis:

The increasing global incidence of psoriasis, including plaque psoriasis—the most common form—fuels demand for effective and long-term treatment solutions.

2. Advancements in Biologic Therapies:

Innovative biologic drugs, particularly monoclonal antibodies targeting specific immune pathways, have significantly improved treatment outcomes, propelling market growth.

3. Favorable Government Initiatives and Reimbursement Policies:

Governments and health organizations are enhancing patient access through public awareness campaigns and insurance coverage, boosting adoption rates.

Restraints:

1. High Cost of Biologic Treatments:

Despite their efficacy, biologics are expensive and may not be accessible to all patients, especially in developing economies.

2. Side Effects and Safety Concerns:

Long-term safety data for new drugs, particularly immunosuppressants, remain a concern, affecting patient adherence and physician prescriptions.

Opportunity:

1. Expansion in Emerging Markets:

Untapped regions such as Asia-Pacific and Latin America offer vast potential for psoriasis drug manufacturers, driven by healthcare infrastructure improvements and increasing diagnostic rates.

2. Development of Personalized Medicine and Topical Innovations:

Advancements in genomics and AI-driven drug development are enabling tailored therapies, while non-invasive topical solutions continue to gain traction.

Market by System Type Insights:

Based on system type, Biologics held the largest market share in 2023. These therapies provide targeted treatment by modulating immune system responses and have been effective in moderate to severe psoriasis cases. Topical therapies remain vital for managing mild conditions, but biologics are projected to witness the fastest growth due to increasing physician and patient preference.

Market by End-use Insights:

By end-use, the Hospital Pharmacy segment dominated in 2023, benefiting from established distribution networks and higher patient trust. Meanwhile, online pharmacies are projected to grow at the highest CAGR, supported by e-commerce expansion, doorstep delivery, and digital healthcare transformation.

Market by Regional Insights:

North America accounted for the largest share of the global psoriasis drug market in 2023, attributed to a high disease burden, favorable reimbursement policies, and widespread access to biologics. However, Asia-Pacific is expected to register the highest growth rate during the forecast period, led by growing healthcare spending, improving access to treatments, and increased awareness campaigns.

Competitive Scenario:

Key players in the global psoriasis drug market include:

AbbVie Inc.

Amgen Inc.

Johnson & Johnson

Novartis AG

Pfizer Inc.

Bristol Myers Squibb

Eli Lilly and Company

UCB S.A.

These companies are focusing on novel product launches, strategic collaborations, and biosimilar development to strengthen their market position. For instance:

In 2023, Eli Lilly launched Mirikizumab, a new IL-23p19 antagonist for moderate to severe plaque psoriasis.

AbbVie expanded the indication of Skyrizi® to include new psoriasis subtypes in 2024.

Novartis continues global expansion of Cosentyx® with favorable real-world efficacy outcomes published in peer-reviewed journals.

Scope of Work – Global Psoriasis Drug Market

Key Market Developments:

2023: FDA approved Mirikizumab by Eli Lilly for plaque psoriasis.

2024: AbbVie expanded Skyrizi®’s label for new psoriasis subtypes.

2024: Novartis presented long-term Cosentyx® data at EADV Congress showcasing sustained efficacy and safety.

FAQs:

1) What is the current market size of the Global Psoriasis Drug Market?

The Global Psoriasis Drug Market was valued at USD 24.6 billion in 2023.

2) What is the major growth driver of the Global Psoriasis Drug Market?

The major driver is the increasing adoption of advanced biologic therapies offering targeted treatment.

3) Which is the largest region during the forecast period in the Global Psoriasis Drug Market?

North America is the largest region due to high disease awareness and access to advanced treatments.

4) Which segment accounted for the largest market share in Global Psoriasis Drug Market?

The Biologics segment accounted for the largest share in 2023.

5) Who are the key market players in the Global Psoriasis Drug Market?

Key players include AbbVie, Amgen, Johnson & Johnson, Novartis, Pfizer, and Eli Lilly.